MENLO PARK, Calif., June 11, 2013 (GLOBE NEWSWIRE) -- IncellDx announced today that it has executed an agreement with Kindstar Global, the largest esoteric diagnostic testing service in China, to offer its proprietary laboratory test for the detection of oncogenic HPV E6, E7 mRNA in China. According to the Company, it believes that this agreement will greatly augment its business presence in Asia.
This test is based upon IncellDx's advanced molecular diagnostic technology for quantifying specific biomarkers that have been associated with an increased risk of progression to cervical cancer, and will broaden Kindstar's current offerings to physicians and hospitals managing diseases associated with women's health. Kindstar will be the first reference laboratory in China to offer this test.
Measuring the potential oncogenic activity of the human papillomavirus (HPV) in infected cervical cells, this novel technology functions by detecting and quantifying the expression of viral oncogenes responsible for triggering progression to cervical cancer, resulting in a higher specificity that existing tests lack.
"Offering this cutting-edge molecular technology to Chinese physicians not only builds our women's health platform, it enhances Kindstar's leading position in the fastest growing market in the world," Kindstar founder and CEO Shiang Huang said.
Bruce K. Patterson MD, founder and CEO of IncellDx, commented, "The high level of specificity our technology produces not only has a significant, positive economic impact on healthcare delivery costs by potentially reducing the number of unnecessary colposcopy/biopsies, but additionally improves patient care by eliminating unnecessary concerns associated with some current results. We are pleased that our partnership with Kindstar will provide better healthcare outcomes for women in China."
About IncellDx, Inc.
IncellDx, Inc. is a molecular diagnostics company dedicated to the detection and monitoring of life threatening diseases such as cervical cancer, breast cancer, HIV/AIDs, hepatitis, and organ transplant rejection. For more information, please visit www.incelldx.com.
CONTACT: Tara Mackay - Investor Relations Coordinator 201-791-2600 x8750Source: IncellDx